Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AbbVie

Humira sales up 19% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AbbVie

3Q Revenues: $4.7 billion (+3%)

3Q Earnings: $964 million (-39%)

YTD Revenues: $13.7 billion (+4%)

YTD Earnings: $3.0 billion (-20%)

Comments: Humira sales were $2.8 billion in the quarter, up 19%. AndroGel and Kaletra sales were down 11% to $248 million and $237 million, respectively. Niaspan sales were down 13% to $201 million. TriCor/Trilipix sales were down 88% to $39 million, due to loss of exclusivity. Synthroid sales were up 23% to $161 million. Creon and Zemplar sales were up 10% to $101 million and $100 million, respectively. R&D expenses were down 12% to $714 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters